Post by
goldtech on Jul 09, 2022 12:44pm
Biogen phase one results
Biogen Idec stock has reached new highs and added $40 billion to the company's market cap as its promising experimental Alzheimer's drug moves forward. The drug was so effective in early human testing that it will immediately skip to final-stage testing needed for approval, This is very optimistic, but a reasonable value would be 4 to 8 Billion. The market knows what a successful drug is worth in revenue and speculation with cause the markets to react.